Bumetanide for thinking skills in children and teens with Down syndrome
Tests bumetanide for thinking abilities in children and teens with Down syndrome.
Key facts
- Who runs it
- Ospedale Pediatrico Bambino Gesu
- Where
- Rome, ItalySee the site
- Registry title
- Assessing the efficacy of Bumetanide for the improvement of cognitive functions in children and adolescents with Down syndrome
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 64 people, planned
- Started
- 11 Jan 2023
- Expected to end
- 31 Dec 2026
- Type of study
- Interventional
- Record updated
- 9 January 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and teenagers with Down syndrome to test whether Bumetanide improves thinking skills, compared with placebo.
- Age
- 10 to 17 years old (included).
- Sex
- All sexes can join.
- Disease stage
- Down syndrome with free trisomy 21 shown by a chromosome test (karyotyping). Mental age between 4.5 and 8.5, measured with the Leiter-3 test.
- Earlier treatment
- People already treated with diuretics (water pills) cannot join.
- Biomarker or test result
- Free trisomy 21 documented by karyotyping.
Main reasons for not taking part
- Hearing loss, serious vision problems or epilepsy
- Serious heart defects that needed or await surgery, or need heart medicines
- Allergy to sulpha drugs, or other reasons Bumetanide cannot be used
- Abnormal blood, liver or kidney test results, or QTc >450 msec on ECG
- Weight less than 25 Kg (55 lb), or pregnancy
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- The presence of a free trisomy 21 documented by karyotyping 2) Adolescents from 10 to 17 years old (included) 3) 4.5 ≥ Mental age ≤ 8.5 (as assessed by Leiter-3 at visit 1 or by assessment with Leiter-3 within 6 months of the first visit (Visit 1) 4) Informed consent from each child and their parents
Who cannot take part
- The presence of any neurosensory deficits, such as hypoacusis or serious visual impairments 2) The presence of epilepsy 3) The presence of electrolyte disorders 4) The presence of clinically and/or hemodynamically significant congenital heart defects, defined as patients with congenital heart disease who already underwent or are awaiting surgical/percutaneous correction (including palliative cardiac surgery as Glenn and/or Fontan) or who are under current treatment with cardiac medications. 5) The presence of a hypersensibility known about sulpha drugs 6) The presence of contraindications relative to the treatment by bumetanide 7) Patients already treated by diuretics 8) Any of the following abnormal laboratory values at screening: - Hemoglobin <10 g/dL - Abnormal liver function defined as any 2 or more of the following: ≥3 × upper limit of normal (ULN) aspartate aminotransferase (AST), ≥3 × ULN alanine aminotransferase (ALT), ≥3 × ULN gamma-glutamyl transpeptidase (GGT), ≥3 × ULN alkaline phosphatase (ALP), or ≥2 × ULN total bilirubin - Abnormal liver function defined as any increase of ≥5 × ULN AST or ALT - Estimated glomerular filtration rate ≤80 mL/min/1.73 m2 (calculated by the Schwartz equation) - Plasma HCO3 > 32 9) A 12-lead ECG demonstrating QTc >450 msec at Screening 10) Subject’s weight less than 25 Kg 11) Pregnancy as assessed by urine beta HCG
Where in Italy
- Ospedale Pediatrico Bambino GesùRome, ItalyTaking people
About the trial
What the trial wants to find out
The aim of the study is to investigate the potential of 3 months of treatment with Bumetanide to rescue cognitive functions and associated psychopathological aspects in DS of Bumetanide treatment in children and adolescents with DS aged 10-16 years. The overreaching goal of our project is to test the ability of a treatment with Bumetanide to rescue cognitive functions and associated psychopathological aspects in children and adolescents with DS. As Bumetanide has been extensively used in the past in humans with little side effects, it is orally active, and it is very economical, we will test here the potentials of our therapeutic approach to be translated directly in a clinical trial on a cohort of DS patients.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A phase 2 double blind placebo controlled study on the efficacy of Bumetanide for cognitive improvement in children and adolescents with Down syndrome
- Plain-language title
- Bumetanide for thinking skills in children and teens with Down syndromeGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 9 January 2026